KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Net Margin (2016 - 2026)

Pacific Biosciences Of California has reported Net Margin over the past 16 years, most recently at 90.43% for Q4 2025.

  • For Q4 2025, Net Margin fell 9647.0% year-over-year to 90.43%; the TTM value through Dec 2025 reached 341.47%, down 14029.0%, while the annual FY2025 figure was 341.47%, 14029.0% down from the prior year.
  • Net Margin for Q4 2025 was 90.43% at Pacific Biosciences Of California, up from 98.85% in the prior quarter.
  • Over five years, Net Margin peaked at 6.04% in Q4 2024 and troughed at 1146.81% in Q1 2025.
  • A 5-year average of 228.78% and a median of 151.94% in 2024 define the central range for Net Margin.
  • On a YoY basis, Net Margin climbed as much as 37583bps in 2025 and fell as far as -94537bps in 2025.
  • Year by year, Net Margin stood at 192.48% in 2021, then plummeted by -60bps to 308.5% in 2022, then soared by 54bps to 140.55% in 2023, then skyrocketed by 104bps to 6.04% in 2024, then tumbled by -1596bps to 90.43% in 2025.
  • Business Quant data shows Net Margin for PACB at 90.43% in Q4 2025, 98.85% in Q3 2025, and 105.44% in Q2 2025.